Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the FDA approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Dr. Wierda reviews how the treatment works, its potential side effects and shares his perspective on what the approval could mean for a broader group of patients in the future.
What Could a New Drug Approval Mean fo... - CLL America Support
What Could a New Drug Approval Mean for CLL Patients?
Written by
mcints
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
A wonderful video with a fantastic Dr.
Jeff
Thanks! He is great!!
Not what you're looking for?
You may also like...
Choice of doctors
Ok so I've got a real dilemma. I'm on W&W. I have two top CLL specialists in two sister hospitals....
Encouraging Tests on Green Tea Extract
A friend just sent me this link. Encouraging. Green Tea Extract in a major scientific study....
I’m unclear what to think of my diagnosis
I’m new here and not clear about the diagnosis given on my Flow Cytometry, which classified me with...
New here. After 10 years of CLL, Ibrutinib treatment needed for decreasing hemoglobin and platelets.
I have avoided any treatment so far but extreme fatigue fluctuations have drastically restricted...
CLL diagnosis and diet
was Diagnosed with CLL a day after my 60th birthday party. I hadn't been feeling well for months. I...
I'm new to the site
Low Platelets
Hubby about to begin Obinutuzumab infusions....feeling anxious
Treatmant for cll
Good News from the Doctor Venetoclax is working!
